Follow-up study on the treatment of Cervical Spondylotic Myelopathy by Yishen Yangsui Recipe

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046514

Enrollment

Unknown

Registered

2021-05-18

Start date

2021-05-22

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical spondylotic myelopathy

Interventions

Experimental group:Yishenyangsui granule (one bag at a time, twice a day, eight weeks) and mecobalamine pill (one pill at a time, three times a day, eight weeks)

Control group:Yishenyangsui granule placebo (one bag at a time, twice a day, eight weeks) and mecobalamine pill (one pill at a time, three times a day, eight weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients completing 6-month follow-up in the previous study; 2.Patients transferred to surgery and terminated during the observation period of 6 months in the previous study.

Exclusion criteria

Exclusion criteria: The cases removed or detached during the observation period of 6 months in the preliminary study.

Design outcomes

Primary

Measure	Time frame
Surgical treatment events;Number Needed to Treat, NNT;	—

Secondary

Measure	Time frame
Survival Analysis;	—

Countries

China

Contacts

Public ContactZhu Liguo

China Academy of Chinese Medical Sciences, Wang Jing Hospital

zhulgwangjing@163.com+86 13488716557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026